

Letters

RESEARCH LETTER

Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection

Myocarditis is a significant cause of sudden cardiac death in competitive athletes and can occur with normal ventricular function.¹ Recent studies have raised concerns of myocardial inflammation after recovery from coronavirus disease 2019 (COVID-19), even in asymptomatic or mildly symptomatic patients.² Our objective was to investigate the use of cardiac magnetic resonance (CMR) imaging in competitive athletes recovered from COVID-19 to detect myocardial inflammation that would identify high-risk athletes for return to competitive play.

Methods | We performed a comprehensive CMR examination including cine, T1 and T2 mapping, extracellular volume fraction, and late gadolinium enhancement (LGE), on a 1.5-T scanner (Magnetom Sola; Siemens Healthineers) using standardized protocols,³ in all competitive athletes referred to the sports medicine clinic after testing positive for COVID-19 (reverse transcriptase-polymerase chain reaction) between June and August 2020. The Ohio State University institutional review board approved the study, and informed consent in writing was obtained from participating athletes. Cardiac magnetic resonance imaging was performed after recommended quarantine (11-53 days). Electrocardiogram, serum troponin I, and transthoracic echocardiogram were performed on day of CMR imaging.

Figure. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From Coronavirus Disease 2019 Infection




Table. Demographic Features and Echocardiographic and Cardiovascular Magnetic Resonance Parameters in Competitive Athletes Recovering From Coronavirus Disease 2019^a

Athlete No.	Sex	Symptoms	Time CMR performed after positive test result, d	Echocardiography, mL/m ²		CMR, %		Native T1, ms	ECV, %	Maximal T2, ms, (AHA segments)	LGE (pattern/AHA segments)	CMR (updated Lake Louise Criteria)
				LVEDV	RVEDV	LVEF	RVEF					
1	Male	No	21	Not done	Not done	60	49	1034	21	51 (9)	Yes (RV insertion; 9)	Normal
2	Male	No	22	51	46	56	59	964	24	48 (9)	Yes (patchy; 6, 8)	Normal
3	Male	No	22	65	60	60	64	953	22	48 (10)	Yes (patchy, 5)	Normal
4	Male	No	15	65	48	59	54	905	20	48 (9)	Yes (linear; 8, 12)	Normal
5	Male	No	17	66	57	55	54	994	24	55 (9)	Yes (epicardial; 3, 9)	Myocarditis
6	Male	Yes	23	73	52	61	62	947	26	63 (3, 9)	Yes (patchy; 3, 9)	Myocarditis
7	Male	Yes	53	66	64	53	52	991	25	49 (7, 9)	Yes (linear, patchy; 8, 9, 12)	Normal
8	Male	No	20	76	36	56	53	963	17	51 (10)	No	Normal
9	Male	Yes	18	60	71	56	52	964	24	52 (7)	Yes (patchy; 3, 9)	Normal
10	Male	Yes	11	67	70	61	58	929	25	58 (8, 9)	Yes (patchy; 2, 3, 8, 9)	Myocarditis
11	Male	No	23	57	49	63	60	987	22	53 (7)	No	Normal
12	Male	Yes	28	72	59	50	53	966	28	53 (7, 8)	No	Normal
13	Male	No	28	81	52	33	53	925	25	53 (7, 8)	No	Normal
14	Male	No	11	46	41	65	54	989	24	53 (8)	No	Normal
15	Male	No	48	56	51	59	57	1003	25	53 (7)	Yes (RV insertion; 9)	Normal
16	Female	Yes	23	68	50	64	58	1001	26	52 (8)	No	Normal
17	Female	Yes	23	55	56	57	60	1030	28	48 (10)	No	Normal
18	Female	No	21	53	35	65	66	1008	25	48 (9)	No	Normal
19	Female	Yes	17	60	32	63	57	978	26	53 (8)	No	Normal
20	Female	No	31	62	51	58	59	1002	25	52 (8)	No	Normal
21	Female	Yes	31	52	40	60	60	946	28	53 (8)	No	Normal
22	Female	Yes	30	67	49	59	64	1000	27	52 (8)	Yes (linear; 12)	Normal
23	Female	Yes	30	58	57	57	55	964	26	53 (11)	No	Normal
24	Female	Yes	26	52	49	55	57	1010	30	53 (10)	No	Normal
25	Female	No	31	56	36	56	56	1027	28	50 (7)	No	Normal
26	Male	No	12	80	44	60	53	969	21	61 (8)	Yes (linear; 8, 9)	Myocarditis

Abbreviations: AHA, American Heart Association; CMR, cardiovascular magnetic resonance imaging; ECV, extracellular volume fraction; EDV, end-diastolic volume; EF, ejection fraction; LGE, late gadolinium enhancement; LV, left ventricular; RV, right ventricular.

^a Symptoms refer to symptoms during short-term infection. Echo volumes were calculated by 3-dimensional method. Cardiovascular magnetic resonance imaging-derived left and right ventricular volumes and function were measured from contiguous short-axis cine images using semiautomated software for endocardial

segmentation using endocardial and epicardial contours at end systole and end diastole per standard protocol. Cardiovascular magnetic resonance imaging-derived myocardial T1 and T2 mapping and ECV were done per standard guidelines. Mean (SD) native T1 less than 999 (31) milliseconds, native T2 of less than 53 milliseconds, and ECV of less than 29% were considered normal per institutional protocol based on phantom and human volunteer experiments. T2 and LGE were only considered significant if seen in 2 orthogonal planes.

Results | We performed CMR imaging in 26 competitive college athletes (mean [SD] age, 19.5 [1.5] years; 15 male [57.7%]) from the following sports: football, soccer, lacrosse, basketball, and track. No athletes required hospitalization or received COVID-19-specific antiviral therapy. Twelve athletes (26.9%; including 7 female individuals) reported mild symptoms during the short-term infection (sore throat, shortness of breath, myalgias, fever), while others were asymptomatic. There were no diagnostic ST/T wave changes on electrocardiogram, and ventricular volumes and function were within the normal range in all athletes by transthoracic echocardiogram and CMR imaging. No athlete had elevated serum levels of troponin I. Four athletes (15%; all male individuals) had CMR findings consistent with myocarditis based on the presence of 2 main features of the updated Lake Louise Criteria: myocardial edema by elevated T2 signal and myocardial injury by presence of nonischemic LGE (**Figure**).⁴ Pericardial effusion was present in 2 athletes with CMR evidence of myocarditis. Two of these 4 athletes with evidence of myocardial inflammation had mild symptoms (shortness of breath), while the other 2 were asymptomatic. Twelve athletes (46%) had LGE (mean of 2 American Heart Association segments), of whom 8 (30.8%) had LGE without concomitant T2 elevation (**Table**). Mean (SD) T2 in those with suspected myocarditis was 59 (3) milliseconds compared with 51 (2) milliseconds in those without CMR evidence of myocarditis.

Discussion | Of 26 competitive athletes, 4 (15%) had CMR findings suggestive of myocarditis and 8 additional athletes (30.8%) exhibited LGE without T2 elevation suggestive of prior myocardial injury. COVID-19-related myocardial injury in competitive athletes and sports participation remains unclear. Cardiac magnetic resonance imaging has the potential to identify a high-risk cohort for adverse outcomes and may, importantly, risk stratify athletes for safe participation because CMR mapping techniques have a high negative predictive value to rule out myocarditis.⁴ A recent study by Puntmann et al² demonstrated cardiac involvement in a significant number of patients who had recovered from COVID-19. A recent expert consensus article recommended 2-week convalescence followed by no diagnostic cardiac testing if asymptomatic and an electrocardiogram and transthoracic echocardiogram in mildly symptomatic athletes with COVID-19 to return to play for competitive sports.⁵ However, emerging knowledge and CMR observations question this recommendation. Cardiac magnetic resonance imaging evidence of myocardial inflammation has been associated with poor outcomes, including myocardial dysfunction and mortality.⁶ Study limitations include lack of baseline CMR imaging and variable timing of CMR imaging from a positive COVID-19 test result. Athletic cardiac adaptation could be responsible for these abnormalities; however, in this cohort, mean (SD) T2 in those with suspected myocarditis was 59 (3) milliseconds vs 51 (2) milliseconds in those without, favoring pathology. Additionally, the rate of LGE (42%) is higher than in previously described normative populations. To conclude, while long-term follow-up and large studies including control populations are required to understand CMR changes

in competitive athletes, CMR may provide an excellent risk-stratification assessment for myocarditis in athletes who have recovered from COVID-19 to guide safe competitive sports participation.

Saurabh Rajpal, MBBS, MD
Matthew S. Tong, DO
James Borchers, MD, MPH
Karolina M. Zareba, MD
Timothy P. Obarski, DO
Orlando P. Simonetti, PhD
Curt J. Daniels, MD

Author Affiliations: The Ohio State University, Columbus.

Corresponding Author: Saurabh Rajpal, MBBS, MD, Division of Cardiology, The Ohio State University, 473 W 12th Ave, Columbus, OH 43210 (saurabh.rajpal@osumc.edu).

Accepted for Publication: August 25, 2020.

Published Online: September 11, 2020. doi:10.1001/jamacardio.2020.4916

Author Contributions: Drs Rajpal and Daniels had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Rajpal, Tong, Borchers, Obarski, Simonetti, Daniels.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Rajpal, Tong, Simonetti.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Rajpal, Tong, Obarski.

Administrative, technical, or material support: Rajpal, Tong, Zareba, Simonetti, Daniels.

Supervision: Rajpal, Tong, Borchers, Daniels.

Conflict of Interest Disclosures: Dr Simonetti reports grants from Siemens, Myocardial Solutions, and Cook Medical outside the submitted work. No other disclosures were reported.

1. Maron BJ, Udelson JE, Bonow RO, et al. American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. *Circulation*. 2015;132(22):e273-e280.

2. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. Published online July 27, 2020. doi:10.1001/jamacardio.2020.3557

3. Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). [published correction appears in *J Cardiovasc Magn Reson*. 2018;20(1):9]. *J Cardiovasc Magn Reson*. 2017;19(1):75. doi:10.1186/s12968-017-0389-8

4. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. *J Am Coll Cardiol*. 2018;72(24):3158-3176. doi:10.1016/j.jacc.2018.09.072

5. Phelan D, Kim JH, Chung EH. A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection. *JAMA Cardiol*. 2020. doi:10.1001/jamacardio.2020.2136

6. Gräni C, Eichhorn C, Bière L, et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. [published correction appears in *J Am Coll Cardiol*. 2017;70(21):2736]. *J Am Coll Cardiol*. 2017;70(16):1964-1976. doi:10.1016/j.jacc.2017.08.050